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Neonatal Exendin-4 Reduces Growth, Fat Deposition and
Glucose Tolerance during Treatment in the Intrauterine
Growth-Restricted Lamb
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Abstract
Background: IUGR increases the risk of type 2 diabetes mellitus (T2DM) in later life, due to reduced insulin sensitivity and
impaired adaptation of insulin secretion. In IUGR rats, development of T2DM can be prevented by neonatal administration
of the GLP-1 analogue exendin-4. We therefore investigated effects of neonatal exendin-4 administration on insulin action
and b-cell mass and function in the IUGR neonate in the sheep, a species with a more developed pancreas at birth.
Methods: Twin IUGR lambs were injected s.c. daily with vehicle (IUGR+Veh, n = 8) or exendin-4 (1 nmol.kg-1, IUGR+Ex-4,
n = 8), and singleton control lambs were injected with vehicle (CON, n = 7), from d 1 to 16 of age. Glucose-stimulated insulin
secretion and insulin sensitivity were measured in vivo during treatment (d 12–14). Body composition, b-cell mass and in
vitro insulin secretion of isolated pancreatic islets were measured at d 16.
Principal Findings: IUGR+Veh did not alter in vivo insulin secretion or insulin sensitivity or b-cell mass, but increased
glucose-stimulated insulin secretion in vitro. Exendin-4 treatment of the IUGR lamb impaired glucose tolerance in vivo,
reflecting reduced insulin sensitivity, and normalised glucose-stimulated insulin secretion in vitro. Exendin-4 also reduced
neonatal growth and visceral fat accumulation in IUGR lambs, known risk factors for later T2DM.
Conclusions: Neonatal exendin-4 induces changes in IUGR lambs that might improve later insulin action. Whether these
effects of exendin-4 lead to improved insulin action in adult life after IUGR in the sheep, as in the PR rat, requires further
investigation.
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Introduction
Small size at birth or intrauterine growth restriction (IUGR)
consistently predicts increased risk of type 2 diabetes mellitus
(T2DM) in human studies [1,2], including independently of
gestation length [3]. This relationship is consistent and significant,
with ,18% of the lifetime risk of T2DM accounted for by poor
growth before birth [4]. Impaired insulin sensitivity and inade-
quate insulin secretion are each implicated as contributing to this
increased risk of T2DM in the IUGR human [1,5,6,7].
Poor fetal growth commonly reflects restricted fetal supply of
oxygen and nutrients due to impaired placental growth and/or
function [8]. In the sheep, surgically-induced restriction of
placental growth (PR) from before mating, and small size at birth,
increase insulin sensitivity in early neonatal life in association with
catch-up growth and increased fat deposition [9,10]. PR
nevertheless impairs glucose-stimulated insulin disposition before
weaning at 1 month of age, and this progresses to impaired insulin
sensitivity and blunted basal and glucose-stimulated insulin
disposition in young adult males at 1 year of age [11,12].
Impaired b-cell function is the primary cause of this inadequate
insulin secretion, which occurs despite increases in b-cell mass in
1-year-old males [12]. Similarly, PR late in pregnancy in rats
produces progeny with normal circulating glucose and insulin
levels at 1 week of age, but mild fasting hyperglycemia and
hyperinsulinemia at 7–10 weeks and frank diabetes by 26 weeks
[13,14]. Impaired b-cell function with later reduction in b-cell
mass is also implicated in decreased insulin secretion in the PR rat
postnatally [13,14]. Excitingly, administration of the GLP-1
analogue exendin-4 to neonatal PR rats normalised subsequent
b-cell mass and insulin secretion and prevented later development
of T2DM [15]. Prevention of T2DM by neonatal exendin-4
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treatment in PR rats is at least partially due to induction and
normalisation of expression of the transcription factor Pdx-1
[15,16], which regulates b-cell function as well as adaptive
increases in b-cell mass [17,18], and is epigenetically down-
regulated in PR rat progeny [19].
The timing of pancreatic development and maturation of b-cell
function, and therefore developmental stages of exposure to IUGR
and neonatal interventions, differs between species. In humans
and sheep, most pancreatic development takes place before birth,
with b-cells present by 0.25 gestation, islets present in mid-
gestation and substantial remodelling to a mature endocrine
pancreas by near term [20,21,22,23]. In both species, b-cell
function is present and matures from mid-gestation onwards
[24,25,26,27]. This functional maturation in humans and sheep
may be driven in part by their pre-partum surge in cortisol. In
contrast, rodents undergo later development of b-cells than sheep
or humans, with b-cells first appearing in late gestation (0.6) and
pancreatic remodelling at ,10-17 d postnatal age [28,29,30].
Neonatal surges in corticosterone and b-cell maturation in rodents
are marked by increased expression of key molecular determinants
of glucose-induced insulin secretion coupling [31] and mitochon-
drial enzymes of the NADH shuttle, essential for stimulation of
insulin secretion by oxidative metabolism [32]. Exendin-4 may in
part be effective in preventing PR programming of reduced b-cell
mass and function in rodents, because it occurs before and during
such maturation. In the present study, we have therefore treated
neonatal IUGR sheep with exendin-4 and assessed whether it is
able to induce changes in growth, insulin action and b-cell mass
and function after IUGR in a species in which the pancreas
undergoes most maturation before birth.
Materials and Methods
Ethics statement
All procedures in this study were approved by the University of
Adelaide Animal Experimentation and Ethics Committee (ap-
proval M-84-2007) and complied with the Australian code of
practice for the care and use of animals for scientific purposes [33].
Animal, treatments and surgery
Australian Merino ewes underwent a timed-mating program,
and pregnancies were confirmed by ultrasound scanning at ,60 d
gestational age (term,150 d). Delivery occurred naturally at term
and the lambs were housed in floor pens with their mothers
throughout the study and allowed to suckle freely, with access to
their mother’s feed and water, except during experimental
protocols as described below. Natural twinning was used to
induce IUGR. Sibling twin lambs were injected with vehicle (0.5%
methanol in 0.9% saline s.c., IUGR+Veh) or exendin-4
(1 nmol.kg21 s.c., IUGR+Ex-4, n = 8), with the first twin pair
randomly allocated to treatments and then the heavier and lighter
birth weight twin alternately allocated in order to balance birth
weights between the two treatments. Exendin-4 (Bachem,
Buberndorf, Germany) was prepared as a 5 nM stock in 0.5%
methanol and 0.9% saline, and stored at 220uC in single use
aliquots, which were thawed immediately prior to injection.
Singleton lambs were injected daily with vehicle (CON, n = 7). All
lambs (singletons and twins) were supplemented with whey protein
(Resource Beneprotein instant protein powder, Nestle, Australia)
given orally in two equal feeds (at 0900–1000 h and 1600–
1700 h), commencing at 1.25 g.kg21.d21 on d 4 and increasing to
5 g.kg21.d21 on and after d 7. Feeding this supplement during this
period of maximal catch-up growth in IUGR lambs [10] was
intended to minimise the potential for limitation of neonatal
growth by milk availability in twins [34] by providing,25% of the
protein expected to be available through milk, and allowing lambs
to self-regulate their milk intake to appetite.
On d 4, catheters were inserted into the lamb’s femoral artery
and vein under general anaesthesia, induced and maintained by
fluothane inhalation anaesthetic, as described previously [10].
Basal blood samples were collected from arterial catheters every
second morning before supplement feeding. Lambs were weighed
at birth and then every 2 d throughout the study. Lamb size was
measured at birth and then every 4 d, and absolute (AGR) and
fractional (FGR) growth rates from birth to d 16 fitted by linear
regression [10].
In vivo measures of insulin secretion, sensitivity, and
action
Glucose tolerance and glucose-stimulated insulin secretion were
measured during an intravenous glucose tolerance test (IVGTT) at
d 14, and indices of glucose tolerance and insulin secretion
calculated as described previously [10,11,35]. The whole body
insulin sensitivity of glucose metabolism was measured by
hyperinsulinemic euglycemic clamp at d 12 [35]. Insulin
sensitivityglucose, the metabolic clearance rate (MCR) of insulin,
basal and maximal post-hepatic insulin delivery rates, and basal
and maximal insulin disposition indices (IDI) were calculated as
described previously [35].
Analysis of plasma insulin and metabolites
Plasma insulin concentrations were measured in duplicate by a
double antibody, solid phase radioimmunoassay using a commer-
cially available kit (Human insulin-specific RIA, HI-14K, Linco
Research Inc., St Charles, MO, USA), which has 100% cross-
reactivity with ovine insulin. The intra-assay coefficients of
variation (CV) for the insulin assay were 7.2% and 5.3%, and
inter-assay CV were 7.0% and 19.6% for QC samples containing
9.9 and 35.9 mU.L21 insulin respectively (n = 10 assays). Plasma
glucose concentrations were measured by colorimetric enzymatic
analysis on a Hitachi 912 automated metabolic analyser using
Roche/Hitachi Glucose/HK kits (Roche Diagnostics GmbH,
Mannheim, Germany).
Post-mortem
Lambs were euthanized by overdose of sodium pentobarbitone
at d 16. Organs (liver, kidneys, lungs, heart), muscles (semitendi-
nosus, gastrocnemius, soleus, tibialis, extensor digitorum longus,
biceps femoris, vastus lateralis, biceps), and dissectable fat depots
(left and right perirenal fat, left and right retroperitoneal fat and
omental fat) were dissected and weighed for each lamb. Dissected
muscle and visceral fat weights were calculated as the sum of
weights of these muscles and fat depots, respectively.
Pancreas and islet isolation and immunostaining and
morphometric analysis
Each pancreas was rapidly dissected and weighed. Represen-
tative mixed aliquots were fixed for 48 h in 4% paraformaldehyde
before embedding in paraffin wax. One section per block was
immunostained to detect insulin-positive cells, and morphometric
analysis of b-cells was performed as described previously, in 20
fields of view per sheep selected by random-systematic sampling
[12]. Measures of in vivo b-cell function were calculated by dividing
total, 1st phase and 2nd phase glucose-stimulated insulin secretion
and basal and maximal IDI by b-cell mass. Pancreatic islets were
obtained by collagenase digestion of pancreas at 35uC for 40 min,
washing and handpicking of islets .100 mm in diameter, with
Neonatal Exendin-4 Treatment in IUGR Sheep
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purity confirmed by immunostaining of aliquots as previously
described [36]. Islet aliquots were cultured overnight at 37uC in
95% O2/5% CO2 in RPMI 1640 media (Sigma Aldrich, Sydney,
Australia).
In vitro b-cell secretion and responses
Static islet incubation and experiments were performed as
previously described [36]. Briefly, for each animal and incubation
condition, triplicate preparations of 10 islets were handpicked into
1.5 mL tubes. Static incubations were performed at 37uC for 1 hr
in KRB/BSA/Forskolin media containing 0, 1.1, 11.1 mM
glucose, or 15 mM KCl, or 11.1 glucose plus 5 mM Lysine,
11.1 glucose plus 5 mM Arginine, 1.1 glucose plus 10 mM
Leucine, 11.1 glucose plus 10mM Epinephrine, or at 0uC for 1 hr
in KRB/BSA/Forskolin media containing 11.1 glucose. Islets
were then centrifuged, supernatant collected for insulin analysis
and DNA was ethanol-extracted from pellets and quantified by
PicoGreen dsDNA Quantification kit (Invitrogen, Melbourne,
Australia). In vitro insulin secretion for each replicate was calculated
as insulin concentration divided by DNA concentration. In vitro
data for an animal was included in analyses provided that insulin
secretion in incubations with KCl (test of maximal release) was
greater than those obtained from incubations with epinephrine or
at 0uC (inhibitory quality controls). Due to technical difficulties
with some preparations, in vitro insulin secretion data was obtained
successfully for 5 CON, 5 IUGR+Veh and 6 IUGR+Ex-4 lambs.
Statistical analysis
Data for non-repeated measures on each animal were analysed
by the mixed models procedure of SPSS for effects of treatment
(fixed effect) and including dam as a random (block) effect in the
model to account for common maternal environment in twins.
Where treatment effects or trends were apparent (P,0.1), we then
compared means by the LSD method, based on a priori questions
to determine: 1. effects of IUGR (CON cf. IUGR+Veh groups), 2.
effects of exendin-4 in IUGR lambs (IUGR+Veh cf. IUGR+Ex-4
groups), and 3. to assess whether exendin-4 restored values to
those of controls (CON cf. IUGR+Ex-4 groups). We also
confirmed these comparisons between IUGR+Veh and IU-
GR+Ex-4 groups using a paired t-test to compare twin siblings,
and the significance of this test was consistent with that for LSD
comparisons for all measures (data not shown). Neonatal growth
patterns and glucose, insulin and insulin:glucose ratios overall and
during 1st phase (0–30 min) and 2nd phase (30–210 min) of insulin
secretion during the IVGTT were analysed by repeated measures
for effects of treatment (between factor), time (within factor) and
interactions, and including dam as a random (block) effect in the
model to account for common maternal environment in twins.
Glucose-stimulated in vitro insulin secretion was analysed by
repeated measures for effects of treatment (between factor), glucose
concentration (within factor) and interactions. Stimulation and
inhibition of in vitro insulin secretion were analysed using repeated
measures models for effects of treatment (between factor),
stimulation (within factor, 11.1 mM glucose or KCl) or inhibition
(within factor, 11.1 mM glucose or epinephrine) and interactions,
Table 1. Effect of IUGR and neonatal exendin-4 on size at birth, postnatal growth and body composition in lambs.
CON IUGR+Veh IUGR+Ex-4 Significance (treatment effect)
Number of animals 7 8 8
Size at birth
Birth weight (kg) 6.0160.21 4.8260.17* 4.8460.15* ,0.001
Crown rump length (cm) 56.361.4 54.661.1 55.161.1 NS
Shoulder height (cm) 44.060.7 40.160.8* 40.960.7* 0.008
Abdominal circumference (cm) 40.160.4 35.160.9* 36.160.6* ,0.001
Body mass index (kg.m22) 19.261.1 16.360.8* 16.060.7* 0.040
Neonatal Growth
AGRweight (g.day
21) 309629 327614 211617*ˆ 0.001
FGRweight (%.day
21) 5.1760.48 6.8660.39 4.3560.32ˆ 0.001
AGRshoulder height (cm.day
21) 0.39060.027 0.50760.037* 0.40360.038ˆ 0.030
FGRshoulder height (%.day
21) 0.8960.06 1.1760.19 1.0060.11 NS
AGRabdominal circumference (cm.day
21) 0.47360.075 0.78260.042* 0.54460.048ˆ 0.002
FGRabdominal circumference (%.day
21) 1.1860.19 2.2560.17* 1.5260.15ˆ 0.001
Postmortem (d 16)
Body weight (kg) 11.060.5 10.160.3 8.3360.25*ˆ ,0.001
Total liver weight (g) 296619 285617 21467*ˆ 0.002
Total liver weight (% of body weight) 2.7060.10 2.8260.14 2.5760.07ˆ NS
Summed muscle mass (g) 265613 22868* 18369*ˆ ,0.001
Summed muscle mass (% of body weight) 2.4260.07 2.2660.04 2.1960.08* 0.055
Visceral fat (g) 132619 118611 41.766.3*ˆ ,0.001
Visceral fat (% of body weight) 1.1960.17 1.1660.09 0.49560.062*ˆ ,0.001
Neonatal growth rates are from d 0 to 16. NS: P.0.1, * different from CON (P,0.05), ˆ different from IUGR+Veh (P,0.05).
doi:10.1371/journal.pone.0056553.t001
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and by mixed model as described above for incubations with
individual secretagogues.
Results
Size at birth, neonatal growth and body composition
Lamb weight, abdominal circumference and body mass index at
birth were reduced in twin lambs (all IUGR groups) compared to
singleton lambs (each P,0.001, Table 1). Absolute and fractional
growth rates for weight and abdominal circumference, and
absolute but not fractional growth rate for shoulder height,
differed with treatment (Table 1). IUGR+Veh lambs had higher
FGR for weight and abdominal circumference than CON lambs
(P = 0.022 and P = 0.001 respectively), and by d 16, there was no
difference in weight between these two groups (Figure 1A). In
control and IUGR+Veh lambs, FGR for weight increased as birth
weight decreased (combined: R =20.700, P = 0.002, n = 15;
Figure 1B), whereas in IUGR+Ex4 lambs, neonatal FGR was
not related to birth weight (P.0.3; Figure 1B). Neonatal exendin-4
treatment reduced neonatal growth rates (Table 1) including
for weight (AGRweight, 235%, P,0.001), linear growth
(AGRshoulder height, 220%, P = 0.031), and organ growth
(AGRabdominal circumference, 230%, P = 0.007), and this group were
lighter than CON and IUGR + Vehlambs at d16 (Figure 1).
Neonatal exendin-4 reduced body weight (218%, P = 0.016) and
relative visceral fat mass (257%, P,0.001) at post-mortem
compared to IUGR+Veh lambs (Table 1). IUGR+Ex-4 lambs
had lower absolute liver weights than CON (228%, P = 0.001) or
IUGR+Veh (225%, P = 0.009) lambs, and lower relative liver
weights (as a proportion of body weight) than IUGR+Veh lambs
(29%, P = 0.021). Absolute summed muscle mass was lower in
IUGR+Veh lambs (23.7%, P = 0.017) relative to CON, and was
decreased by exendin-4 treatment relative to CON (227%,
P,0.001) and IUGR+Veh (225%, P = 0.004) groups. Relative
summed muscle weight also tended to be lower in IUGR+Veh
(27.6%, P = 0.093) and was lower in IUGR+Ex-4 (29.5%,
P = 0.019) compared to CON lambs (Table 1).
Insulin secretion, sensitivity and action
Fasting glucose and insulin levels, glucose tolerance and overall,
1st phase and 2nd phase insulin secretion in vivo were similar in
IUGR+Veh and CON lambs (each P.0.1, Table 2). Fasting
plasma glucose (d 14) was reduced in IUGR+Ex-4 lambs
compared to CON (210%, P = 0.022) and IUGR+Veh lambs
(29%, P = 0.019, Table 2). Conversely, glucose tolerance was
impaired (increased glucose AUC) in IUGR+Ex-4 lambs overall
(+132%, +156% respectively), during first phase insulin secretion
(+41%, +57%), and during second phase insulin secretion
compared to CON and IUGR+Veh lambs (each P#0.02,
Table 2). Across the whole of the IVGTT, and within the 1st
phase of insulin secretion, plasma glucose (Figure 2) changed with
time (each P,0.001). Fasting plasma glucose in fasting samples
was lower in IUGR+Ex4 than in IUGR+Veh lambs (P,0.001),
and tended to be lower in IUGR+Ex4 than in CON lambs
(P = 0.091). Conversely, plasma glucose during the 1st phase of
insulin secretion was higher in IUGR+Ex4 than in IUGR+Veh
lambs (P,0.001), and plasma glucose during the 2nd phase of
insulin secretion did not differ between groups (P.0.3). The
pattern of change in plasma glucose with time differed between
groups overall (P,0.001) and during the 1st phase of insulin
secretion (P = 0.003). Fasting plasma insulin in absolute terms and
relative to glucose, and insulin secretion (assessed relative to the
glucose stimulus as AUC insulin/AUC glucose) did not differ
between the groups (Table 2 and Figure 2). Plasma insulin
(Figure 2) changed with time throughout the IVGTT (P,0.001),
and within 1st (P,0.001) and 2nd phase (P = 0.008) of insulin
response. The ratio of plasma insulin to glucose (Figure 2), an
index of insulin secretion, similarly changed with time throughout
the IVGTT (P,0.001), and within 1st (P = 0.015) and 2nd phase
(P = 0.005) of insulin response. Plasma insulin concentrations and
the ratio of plasma insulin to glucose ratios during the IVGTT
(Figure 2) were higher in IUGR+Ex4 than in IUGR+Veh lambs
overall (each P,0.001) and during the 2nd phase of insulin
secretion (each P,0.001), and did not differ between other
treatment groups. IUGR+Ex-4 lambs had lower insulin sensitivity
compared to CON (244%, P = 0.004) and IUGR+Veh lambs
(246%, P = 0.002, Table 2). Basal and maximal insulin disposition
indices did not differ between groups (Table 2).
Pancreas morphology and b-cell function
Absolute and relative pancreas weights, and numbers of b-cells
per islet, b-cell volume density and absolute b-cell mass did not
differ with treatment (Table 3). b-cell mass relative to body weight
was greater in IUGR+Ex-4 lambs than CON lambs (+36%,
Figure 1. Effect of IUGR and neonatal exendin-4 treatment on
neonatal growth. Neonatal exendin-4 treatment reduced weight of
twin IUGR lambs from 8 days of age (A), and abolished the negative
relationship between birth weight and neonatal fractional growth rate
(B). CON (white circle) and IUGR+Veh (black circle) lambs were treated
once daily with vehicle (0.5% methanol in saline s.c.) and IUGR+Ex-4
(gray square) lambs were treated once daily with exendin-4
(1 nmol.kg21 s.c.). Data in Figure 1A are means 6 SEM, and data in
Figure 1B are individual animal outcomes. * different from CON
(P,0.05),ˆ different from IUGR+Veh (P,0.05).
doi:10.1371/journal.pone.0056553.g001
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P = 0.039, Table 3). IUGR+Ex-4 lambs also tended to have higher
relative b-cell mass than IUGR+Veh lambs (+28%, P = 0.083,
Table 3). Measures of b-cell function did not differ between
treatments (Table 3).
In vitro b-cell secretory function
Islet insulin secretion (Figure 3) increased with increasing
glucose concentration between 0 and 11.1 mM overall (P = 0.006).
Glucose-stimulated insulin secretion tended to be higher overall in
IUGR+Veh compared to CON lambs (+420%, P = 0.081), did not
differ between IUGR+Ex4 lambs and CON lambs (P = 0.9) and
tended to be higher in IUGR+Veh lambs than in IUGR+Ex4
lambs (+20%, P = 0.087). At the highest glucose concentration
(11.1 mM), IUGR +Vehlambs had higher insulin secretion than
CON lambs (+66%, P = 0.046) and tended to have higher insulin
secretion than IUGR+Ex-4 lambs (+58%, P = 0.066 respectively,
Figure 3). Within each group of lambs, in vitro insulin secretion at
11.1 mM glucose was between 1.6 and 2-fold higher than that at
0 mM glucose (Figure 3). In vitro insulin secretion was similar
from islets incubated with 15 mM KCl or 11.1 mM glucose
(P.0.5), and the response to KCl was similar between treatments
(P.0.8). In vitro insulin secretion was suppressed by epinephrine
treatment compared to glucose-stimulated insulin secretion
(262%, P = 0.001). Suppression of glucose-stimulated insulin
secretion by epinephrine was greater in IUGR+Veh than CON
lambs in absolute terms (2173 cf. 247 mU insulin/mgDNA,
P = 0.044), but not as a proportion of insulin secretion in the
absence of epinephrine (228.8% cf. 27.8%, P = 0.274). Epineph-
rine suppression of glucose-stimulated insulin secretion was similar
in islets from IUGR-Ex4 to that in other groups (P.0.1 for each).
Lysine-, arginine- and leucine-stimulated in vitro islet insulin
secretion did not differ between treatment groups (each P.0.3,
data not shown).
Discussion
In the present study, twin IUGR lambs caught up in weight by
16 d of age, and had normal in vivo insulin action in their second
week of life, with similar b-cell mass to singleton control lambs.
Glucose-stimulated in vitro insulin secretion was increased in the
IUGR twin lamb relative to controls, suggesting up-regulated b-
cell function at this age. Daily exendin-4 treatment of twin IUGR
lambs during neonatal life prevented catch-up growth and fat
accumulation, and normalised in vitro insulin secretion from their
islets, relative to untreated IUGR twins, which may retain
adaptive capacity for later life. Glucose tolerance of IUGR lambs
was impaired during exendin-4 treatment however, reflecting
decreased insulin sensitivity and occurred despite greater in vivo
insulin secretion. This may be due to central actions of exendin-4
to inhibit food intake and insulin sensitivity [37,38,39]. Neverthe-
less, the reduction in fat accumulation and normalised b-cell
action in vitro of IUGR lambs suggest that neonatal exendin-4
might have beneficial effects on insulin-regulated glucose homeo-
stasis in later life. These outcomes also demonstrate the biological
activity of exendin-4 for the first time in the sheep, at least in the
context of individuals who had undergone growth-restriction
before birth.
We found similar growth and metabolic responses to IUGR
induced by twinning in this study to those seen previously after
IUGR induced by restriction of placental growth and function
(PR) in sheep. Like the PR lamb, the twin IUGR lambs in the
Table 2. Effect of IUGR and neonatal exendin-4 on insulin action in lambs.
CON IUGR+Veh IUGR+Ex-4 Significance (treatment effect)
Number of animals 7 8 8
Fasting
Plasma glucose (mmol.L21) 6.4760.26 6.4060.11 5.8160.12*ˆ 0.008
Plasma insulin (mU.L21) 20.466.0 15.462.2 16.462.2 NS
Plasma insulin:glucose (mU.mmol21) 3.3061.11 2.4060.35 2.8360.38 NS
AUC glucose (mmol.min.L21)
Total 6266 5663 143628*ˆ 0.003
1st phase 60.965.4 54.862.9 86.265.7*ˆ ,0.001
2nd phase 161 161 57624*ˆ 0.017
AUC insulin (mU.min.L21)
Total 5876184 5906181 8636178 NS
1st phase 4996133 5796180 6506128 NS
2nd phase 88661 1266 2136119 NS
AUC insulin:AUC glucose (mU.mmol21)
Total 10.864.3 10.963.6 7.661.9 NS
1st phase 8.962.8 10.763.5 7.861.6 NS
2nd phase 26.5625.9 0.360.3 9.662.8 NS
Insulin sensitivity (mg.L.mU21.kg21.min21) 0.09760.010 0.10060.011 0.04760.009*ˆ 0.003
Basal IDI (mg.mL.kg22.min22) 69.7631.2 39.565.5 28.4610.0 NS
Maximal IDI (mg.mL.kg22.min22) 138628 119627 97637 NS
Glucose and insulin AUC were measured during an IVGTT (0.25 g glucose.kg21) at d 14. 1st and 2nd phase values for insulin and glucose were measured from 0–30 and
from 30–210 minutes after glucose administration, respectively. Insulin sensitivity was measured during a hyperinsulinemic euglycemic clamp (2 mU insulin.kg-1.min21)
at d 12. NS: P.0.1, * different from CON (P,0.05), ˆ different from IUGR+Veh (P,0.05).
doi:10.1371/journal.pone.0056553.t002
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present study experienced accelerated neonatal catch-up growth,
achieving a normal body weight by 16 d of age in this study and
by 30 d of age in our studies in PR lambs [40]. Accelerated fat
deposition occurs during accelerated neonatal growth, and in
humans catch-up growth is a risk factor for later obesity [41]. PR
lambs have fat stores proportionate to their reduced body weight
in late gestation [42], and similar to our twin lambs at 16 days in
the present study, fat mass relative to body weight is similar in PR
and CON lambs at 21 days despite their catch up growth [43]. By
43 days of age, however, the accelerated fat deposition results in
greater visceral fat in PR lambs than their control counterparts
[40]. Small size at birth in humans consistently induces insulin
resistance in adults and adolescents [44], but this is preceded by
enhanced insulin sensitivity in neonates, which reverses to
resistance in association with catch-up growth in the first few
years of life [45]. There is similar evidence of a reversal from
insulin sensitivity to insulin resistance in the lamb following IUGR
induced by restriction of placental growth and function (PR). The
young PR lamb at 21 days of age has increased expression of
insulin receptors and insulin signalling molecules in skeletal muscle
[46], although in vivo insulin action was not measured. At 30 days,
glucose tolerance of PR lambs is normal, despite decreased insulin
action caused by falls in both in vivo insulin secretion and insulin
sensitivity [40,47]. The latter reflects decreased expression of
insulin-signalling pathways in skeletal muscle [47]. Impaired
glucose tolerance and elevated fasting glucose emerge by 1 year
of age in IUGR sheep [48]. The normal insulin sensitivity and
glucose tolerance seen here in the twin IUGR lamb may therefore
reflect the beginnings of the reversal from insulin sensitivity to
insulin resistance occurring during the neonatal catch-up growth
they are experiencing at this age.
Neither IUGR nor neonatal exendin-4 treatment in IUGR
lambs altered relative b-cell mass at 16 days in the present study,
consistent with the lack of effect of PR and neonatal exendin-4
treatment on b-cell mass in young postnatal rats at 2 weeks of age
[49]. In the rat, reduced b-cell mass after IUGR emerges by 3
months of age in young adults, and neonatal exendin-4 treatment
normalises adult b-cell mass at this age in this model [49]. We
hypothesise that these beneficial effects of exendin-4 treatment
after IUGR might also emerge with ageing in the sheep. This lack
of an immediate response may also reflect the collection of
pancreas soon after completion of exendin-4 treatment here and in
PR rats. Previous rodent studies have reported increased b-cell
replication after similar exendin-4 treatment durations, but
differences in b-cell mass are sometimes not apparent until several
weeks later [50,51]. Many of the actions of exendin-4 and GLP-1
on insulin secretion are mediated via stimulation of Pdx-1
expression, a transcription factor important for regulation of b-
cell mass as well as function, and which is required for plasticity of
b-cell mass and function to increase insulin secretion in response to
demand. In the PR rat, prevention of later diabetes following
neonatal exendin-4 treatment reflects reversal of epigenetic
changes induced by PR in the Pdx-1 promoter by late gestation,
that normally worsen with age and lead to decreased Pdx-1
expression, loss of b-cell function and subsequent loss of b-cell
mass postnatally [15,16,19]. Intriguingly, although neonatal
exendin-4 induces epigenetic changes such as increased acetylation
and lysine 4 trimethylation at histone H3 in control as well as PR
rat juveniles, it only increases Pdx-1 expression and b-cell mass and
improves glucose tolerance in the PR progeny [15,16,19]. Indeed,
the Pdx-1 promotor becomes methylated and hence partially
silenced by adulthood in untreated PR rat progeny, but not in
control progeny regardless of exendin-4 treatment, which implies
that the levels of histone 3 acetylation and lysine 4 trimethylation
in untreated control progeny is already sufficient to prevent later
promoter methylation [16]. We do not yet know whether neonatal
exendin-4 treatment will affect outcomes in control sheep progeny,
as the aim of the present study was to evaluate its efficacy only in
the context of IUGR. Whether neonatal exendin-4 acts similarly
in the IUGR lamb as in the PR rat, by reversing epigenetic
changes in the Pdx-1 promotor and improves adult b-cell mass and
function to delay or prevent the subsequent loss of insulin secretory
capacity observed after IUGR in young adult male sheep [11]
remains to be determined, and will require separate animal
Figure 2. Effect of IUGR and neonatal exendin-4 treatment on
in vivo metabolism in young lambs. Glucose tolerance (A), glucose-
stimulated insulin secretion (B) and relative glucose-stimulated insulin
secretion (C) were measured during an intravenous glucose tolerance
test 14 days of age. CON (white circle, n = 7), IUGR+Veh (black circle,
n = 8) and IUGR+Ex-4 (gray square, n = 8). Data are means 6 SEM. *
different from CON (P,0.05).
doi:10.1371/journal.pone.0056553.g002
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cohorts with long-term follow-up of functional and molecular
outcomes
In this study, the decrease in fasting plasma glucose (,9%) and
more sustained insulin secretion during exendin-4 treatment in the
IUGR neonatal lamb compared to untreated IUGR siblings were
generally consistent with responses to exendin-4 in rodents and
humans. Medium- to long-term exendin-4 treatment in human
T2DM patients (daily 5–10 mg injections for 30 and 82 weeks)
[52,53,54], in the obese diabetic db/db mouse (1 nmol.kg21.d21 as
daily injections for 14 days) [55], and in the obese ob/ob mouse
(20 mg.kg21.d21, , 5 nmol.kg21.d21 as twice daily injections for
60 days) [56] reduces fasting blood glucose as well as HbA1c, a
marker of chronic hyperglycemia. Earlier studies in humans also
demonstrated acute decreases in fasting and post-prandial glucose
concentrations after a single exendin-4 dose and after 5 days of
twice daily injections with 5 mg exendin-4 [57]. Infusions with
GLP-1 and chronic exendin-4 treatment enhance post-prandial
and glucose-stimulated insulin secretion in human patients with
T2DM, including restoration of 1st phase insulin secretion
response to glucose, and sustained elevation of 2nd phase insulin
secretion in T2DM patients [57,58,59]. In the diabetic rat, four
weeks of twice-daily exendin-4 injections (105 pmol.kg21)
increased 1st and 2nd phase insulin secretion during a hypergly-
cemic clamp [60]. Whilst we similarly observed increases in second
phase insulin secretion in IUGR lambs during exendin-4
treatment, their first phase insulin secretion was unchanged. This
apparent difference may be because first phase insulin secretion is
normal in the IUGR lamb at this age, whereas previous reports of
increased first phase insulin responses after exendin-4 or GLP-1
treatment have all been in the context of diabetes, when first phase
Figure 3. Effect of IUGR and neonatal exendin-4 treatment on in vitro insulin secretion from isolated islets in response to glucose
and potassium chloride. CON (white bar, n = 5), IUGR+Veh (black bar, n = 5) and IUGR+Ex-4 (gray bar, n = 6). Data are means 6 SEM. Specific
contrasts: * P,0.05, # P,0.10.
doi:10.1371/journal.pone.0056553.g003
Table 3. Effect of IUGR and neonatal exendin-4 on pancreas morphology and b-cell function.
CON (7) IUGR+Veh (8) IUGR+Ex-4 (8) Significance (treatment effect)
Pancreas morphology
Pancreas weight (g) 10.861.5 8.5360.93 7.9060.55 NS
Pancreas (% of body weight) 0.10360.019 0.08560.009 0.09660.007 NS
b-cell volume density 0.03360.005 0.04060.003 0.04960.007 NS
b-cell mass (g) 0.32660.038 0.34560.054 0.38760.055 NS
b-cell mass (% of body weight) 0.003060.0004 0.003460.0005 0.004760.0006* 0.070
Islet density (no.mm22) 66.369.7 76.9610.3 91.6610.5 NS
b-cells/islets 10.961.4 10.561.3 12.961.3 NS
% of islets with ,5b-cells 27.766.3 23.866.4 31.366.7 NS
b-cell function
Insulin secretion (AUC ins) per b-cell mass
(mU.min.L21.g21)
16826413 19446588 21906286 NS
Basal IDI per b-cell mass (mg.mL.kg22.min22.g21) 187660 129625 85.4626.5 NS
Max IDI per b-cell mass
(mg.mL.kg22.min22.g21)
441685 389689 269694 NS
NS: P.0.1, * different from CON (P,0.05).
doi:10.1371/journal.pone.0056553.t003
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secretion is impaired. The effects of exendin-4 on insulin secretion
in IUGR sheep AFTER cessation of treatment remain to be
investigated.
We performed in vitro testing to measure intrinsic b-cell function
independent of systemic input from endocrine and nervous
systems [36]. In this study, IUGR neonatal lambs had enhanced
in vitro glucose-stimulated insulin secretion, or b-cell hypersecretion
relative to control lambs, which occurs in obese individuals, as well
as early in the pathogenesis of type 2 diabetes [61,62,63].
Interestingly, exendin-4 treatment of IUGR lambs abolished this
in vitro insulin hypersecretion from isolated islets, suggesting some
normalisation of intrinsic b-cell function and its determinants.
Together with increased b-cell mass, this suggests that neonatal
exendin-4 may improve insulin secretory capacity after IUGR.
In contrast with the improved insulin sensitivity seen after
chronic GLP-1 or exendin-4 treatment in human patients with
extreme obesity [64] or T2DM [65], insulin sensitivity was
profoundly decreased on the 11th day of exendin-4 treatment in
neonatal IUGR lambs, relative to their untreated IUGR
littermates. In studies of exendin-4 action in rodents, direct
measures and calculated indices of insulin sensitivity have either
been increased [56,60,66], or not altered [55], immediately
following or during chronic (2 – 9 weeks) exendin-4 treatment.
We propose that the differential effects of exendin-4 on insulin
sensitivity may depend on whether the latter is assessed during
treatment or after, whether the subjects are obese and on their
developmental stage and growth rate. Exendin-4 reduced weight
gain in the IUGR lambs in the present study as well as in PR rat
neonates [15], consistent with its actions including decreased food
and caloric intake, reduced gastric emptying and induced weight
loss or slowed weight gain in mice and rats [67,68] and in
adolescent and adult humans [52,53,54,64,69,70,71]. It appears
that restricted nutrition reduces insulin sensitivity in growing
animals, possibly partly due to reduced mass of insulin-responsive
tissues, whereas in older or obese animals the net effect of
restricted feeding and consequently reduced fatness is to increase
insulin sensitivity. Thus, feed restriction increases insulin-stimulated
glucose metabolism and insulin sensitivity in adult sheep [72], but
decreases insulin-stimulated glucose uptake in muscle of young
growing pigs [73]. In mice, exendin-4 can cross the blood-brain
barrier [74], and acts centrally to suppress femoral blood flow and
whole body insulin sensitivity, via the GLP-1 receptor and
activation of PKC-d signalling pathways in the hypothalamus
[37,38], suggesting an additional mechanism for decreased
peripheral insulin sensitivity during exendin-4 treatment. As a
consequence of their reduced insulin sensitivity, and despite the
increased 2nd phase insulin secretion that maintained insulin
disposition, glucose tolerance was impaired in IUGR+Ex-4 lambs
compared to IUGR+Veh and CON lambs. This contrasts with
improved glucose tolerance observed 24 h after completion of
medium- to long-term exendin-4 treatment in mature rats
[56,59,60,66], during continued long-term exendin-4 treatment
in b-cell depleted rats [75], and acutely in T2DM human patients
[76]. In some of these studies, the improved glucose tolerance
during or after exendin-4 treatment reflects marked improvement
of deficient insulin secretion due to stimulation of b-cell
regeneration [75] or up-regulation of b-cell function in T2DM
patients [76]. Long-term exendin-4 treatment increases insulin
sensitivity in obese humans, genetically-obese rodents and diabetic
humans and rodents, measured either during or 16–24 h after
completion of treatment [56,64,77,78]. Improved whole-body
insulin sensitivity is probably also due to improvements in hepatic
insulin sensitivity, with lower post-prandial endogenous glucose
production after or during exendin-4 treatment [79]. To our
knowledge, this is the first study of the effects of exendin-4 on
insulin action treatment in young growing animals. Further studies
are needed to define the underlying mechanisms for their reduced
insulin sensitivity during treatment.
The profound reduction in visceral fat deposition after IUGR in
response to exendin-4 is also of particular potential importance for
later glucose homeostasis, given that obesity and particularly
visceral fat deposition are strong risk factors for impaired glucose
tolerance and T2DM [80,81]. In the PR rat, neonatal exendin-4
reduces weight gain in conjunction with prevention of later
diabetes, and this may particularly reduce the risk of T2DM in
IUGR subjects [15], since catch-up growth after IUGR is a risk
factor for T2DM and for adult obesity [82,83]. Intriguingly,
neonatal exendin-4 treatment abolished the negative relationship
between birth weight and fractional growth rate in IUGR lambs in
the current study. In contrast to its metabolic effects, exendin-4
reduced neonatal growth and adult size in both control and PR rat
progeny [15]. This suggests that exendin-4 may act in part, but not
only, via the pathway/s responsible for catch-up after IUGR,
which include neonatal hyperphagia, elevated insulin sensitivity
and increased abundance of thyroid hormones in IUGR lambs
[40,84,85]. Longer-term evaluations of growth and composition
after cessation of exendin-4 are needed to determine whether this
decrease in central adiposity persists in the IUGR sheep.
In conclusion, neonatal exendin-4 treatment increased 2nd
phase insulin secretion in vivo, normalised in vitro insulin secretion
and decreased visceral fat at the end of treatment in the IUGR
lamb. Neonatal exendin-4 treatment also improves insulin
secretion and glucose tolerance in adolescent and adult rat
progeny following IUGR, preventing development of diabetes in
these animals [15], although the effects during treatment were not
measured in the latter study. Investigation of the long-term effects
of neonatal exendin-4 on glucose homeostasis and insulin action in
the IUGR lamb into adulthood should be a priority for the future.
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